Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study

BACKGROUND: With the first and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), clinical benefit and rash correlate together. EGFR TKI-induced rash can be alleviated with tetracyclines, but it is unknown whether the use of tetracyclines can increase the su...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:ESMO Open
Egile Nagusiak: Alanen, Virve, Iivanainen, Sanna, Arffman, Martti, Koivunen, Jussi Pekka
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2020
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7580060/
https://ncbi.nlm.nih.gov/pubmed/33087401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2020-000864
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak